Screener
Beam Therapeutics BEAM Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchases of property and equipment | (2,232) | (3,065) |
| Purchases of marketable securities | (153,792) | (339,169) |
| Maturities of marketable securities | 181,293 | 217,145 |
| Net cash provided by (used in) investing activities | 25,269 | (125,089) |
| Financing activities | ||
| Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs | — | 471,159 |
| Proceeds from issuances of stock under ESPP | 1,510 | 1,501 |
| Proceeds from exercise of stock options | 2,025 | 719 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's investing cash flow?
- Beam Therapeutics (BEAM) reported investing cash flow of $25.27M in Q1 2026.
- How has Beam Therapeutics's investing cash flow changed year-over-year?
- Beam Therapeutics's investing cash flow increased by 120.2% year-over-year, from -$125.09M to $25.27M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Beam Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude